Clinical trials: Histological Response
Multiple Myeloma, Non-Hodgkins Lymphoma
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant
Plerixafor, administered at a dose of 240 ug/kg, potentiates the effect of granulocyte colony-stimulating factor (G-CSF) to increase peripheral blood progenitor cells in both healthy volunteers and cancer patients.
- Conditions
- Multiple Myeloma, Non-Hodgkins Lymphoma, Hodgkins Disease
- Trial name
- NCT00901225
- Testing
- G-CSF plus Plerixafor
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Duke University
Soft Tissue Sarcoma
Neoadyuvant High-dose of Ifosfamide and Concurrent Radiotherapy in Soft Tissue Sarcoma
To study the activity and toxicity of a neoadjuvant regimen including high-dose ifosfamide in combination with radiotherapy, and subsequent surgery, in high-risk soft tissue sarcomas.
- Trial name
- NCT01102608
- Testing
- Ifosfamide
- Where
- Spain
- Volunteers
- 32 people
- Sponsor
- Grupo Espanol de Investigacion en Sarcomas
Acute Myeloid Leukemia
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
To assess the safety and efficacy of galinpepimut-S (GPS) compared with investigator's choice of best available therapy (BAT) on overall survival (OS) in subjects with acute myeloid leukemia (AML) who are in second or later…
- Trial name
- REGAL (NCT04229979)
- Testing
- Galinpepimut-S, Azacitidine, Venetoclax
- Where
- 73 sites in United States, France and 8 more
- Volunteers
- 127 people
- Sponsor
- Sellas Life Sciences Group
Hepatocellular Carcinoma
DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC
The main objective is to evaluate the value of dynamic contrast-enhanced Magnetic Resonance Imaging (DCE-MRI) in prediction of response of patients with hepatocellular carcinoma (HCC) to treatment with Sorafenib assessed by…
- Trial name
- DCE-MRI (NCT01806740)
- Testing
- Gadoterate meglumine
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Guerbet
Hepatocellular Carcinoma
Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma
Atezolizumab (anti-programmed death-ligand 1; anti-PD-L1) in conjunction with bevacizumab (anti-vascular endothelial growth factor; anti-VEGF) has become the established standard first-line systemic treatment for unresectable…
- Trial name
- PhotonAB (NCT06339424)
- Testing
- Atezolizumab, Bevacizumab, Photon radiotherapy
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- Chang Gung Memorial Hospital
Adult Glioblastoma, Magnetic Resonance Imaging
Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastoma
This study aims to evaluate whether pre-treatment MRI can be used to predict treatment response for anti-angiogenic treatment in glioblastomas.
- Conditions
- Adult Glioblastoma, Magnetic Resonance Imaging, Bevacizimab
- Trial name
- NCT04143425
- Testing
- 3-Tesla conventional magnetic resonance imaging, Advanced imaging without contrast use, Dynamic susceptibility contrast-weighted imaging
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- Ho Sung Kim
Leukemia
S9031-S9333-S0112-S0301-A Biomarkers Associated With Response to Cytarabine in Samples From Older Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of blood and tissue from patients with cancer treated with cytarabine in the laboratory may help doctors learn more about the effects of cytarabine on cells.
- Trial name
- NCT01338974
- Testing
- gene expression analysis, proteomic profiling, flow cytometry
- Volunteers
- 290 people
- Sponsor
- SWOG Cancer Research Network
Acute Myeloid Leukemia (AML)
Venetoclax TDM in Newly Diagnosed AML: Exposure-Response and Prognosis
Venetoclax combined with azacitidine (VEN-AZA) is the current first-line standard of care for newly diagnosed acute myeloid leukemia (AML) patients unfit for intensive chemotherapy.
- Trial name
- ND-AML (NCT07670130)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Nasopharyngeal Carcinoma, Pathologic Complete Response
The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC
This study aims to explore the prognostic value of pathological remission after one cycle of induction chemotherapy in locally advanced nasopharyngeal carcinoma, and the change of immune micro-environment after one cycle…
- Conditions
- Nasopharyngeal Carcinoma, Pathologic Complete Response, Tumor Microenvironment
- Trial name
- NCT06182657
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
NSCLC, Melanoma
Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response
Immunotherapy with agents stimulating the immune system to act against cancer are now a new standard of care in various cancers as lung cancer and melanoma, but also bladder cancer, kidney cancer and head \& neck cancer.
- Conditions
- NSCLC, Melanoma, Kidney Cancer, Urothelial Carcinoma
- Trial name
- NCT04146064
- Testing
- Breathprint analysis and patient-reported outcomes
- Where
- Canada
- Volunteers
- 190 people
- Sponsor
- University Health Network, Toronto
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer
This phase I trial studies the side effects and best dose of autologous dendritic cells in treating patients with metastatic kidney cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT01826877
- Testing
- AdGMCAIX-transduced autologous dendritic cells, therapeutic autologous dendritic cells, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Poorly Differentiated Malignant Neuroendocrine Carcinoma, Neuroendocrine Carcinoma, Grade 3
Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study
The study is designed as an open-label, prospective, single arm, multicenter study of everolimus in histologically confirmed, neuroendocrine carcinoma G3 /neuroendocrine tumor G3 after failure of first-line platin-based…
- Conditions
- Poorly Differentiated Malignant Neuroendocrine Carcinoma, Neuroendocrine Carcinoma, Grade 3, Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3, Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3
- Trial name
- EVINEC (NCT02113800)
- Testing
- Everolimus (Afinitor®)
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- AIO-Studien-gGmbH
Multiple Myeloma
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple myeloma is characterized by a pattern of recurrent relapse and remains an incurable malignancy. Participants with minimal residual disease (MRD) after front line therapy with induction and transplant have worse prognosis…
- Trial name
- ROTATE (NCT06993675)
- Testing
- Talquetamab, Teclistamab
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Noffar Bar
Sensitivity, Specificity
Clinical Evaluation for Sarcoma Originated From Bone
Response Evaluation Criteria in Solid Tumors (RECIST) are insensitive in evaluating primary sarcoma originated from bone treated with chemotherapy or targeted therapy, which did not have the definition of measurement methods…
- Conditions
- Sensitivity, Specificity, Histological Response, Survival
- Trial name
- CESOFB (NCT03358992)
- Where
- 3 sites in China
- Volunteers
- 300 people
- Sponsor
- Peking University People's Hospital
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA
ARTemIS-Eso is a phase I-II, three-level, open-label trial with a dose-expansion cohort at recommended schedule in both esophageal cancer histological groups (squamous cell carcinoma and adenocarcinoma) of RCT and ImT…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Squamous Cell Carcinoma of the Esophagus
- Trial name
- ARTEMIS-Eso (NCT03307941)
- Testing
- Monalizumab, Oxaliplatin, 5-Fluorouracil
- Where
- Belgium
- Sponsor
- Jules Bordet Institute
Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs
The study is designed to compare the efficacy of ELVN-001 versus Investigator-selected tyrosine kinase inhibitor (TKI) for adults with previously treated chronic myeloid leukemia in the chronic phase (CP-CML).
- Conditions
- Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive, Chronic Phase Chronic Myeloid Leukemia, BCR::ABL1 Positive CML
- Trial name
- ENABLE-2 (NCT07905183)
- Testing
- ELVN-001, TKI
- Volunteers
- 450 people
- Sponsor
- Enliven Therapeutics
Hepatocellular Carcinoma, Liver Cancer
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer
Background: Primary Liver Cancer is the second most common cause of cancer-related death worldwide. It is the cancer with the fastest rising incidence and mortality in the United States.
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Cholangiocarcinoma
- Trial name
- NCT04145141
- Where
- 4 sites in United States
- Volunteers
- 132 people
- Sponsor
- National Cancer Institute (NCI)
Cholangiocarcinoma
International Registry on Cholangiocarcinoma Treatment
Cholangiocarcinoma is a rare and very aggressive neoplasm that arises from the biliary epithelium, constitutes approximately 2% of all reported cancer, and accounts for about 3% of all gastrointestinal malignancies.
- Trial name
- CHOLANGIO (NCT01920503)
- Testing
- Doxorubicin
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- International Group of Endovascular Oncology
Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
This 2 arm study will compare the efficacy and safety of the standard chemotherapy of the East German Study Group for Hematology and Oncology versus standard chemotherapy plus MabThera (375mg/m2 iv, once monthly for 8 cycles) in…
- Trial name
- NCT00269113
- Testing
- rituximab [MabThera/Rituxan], Standard chemotherapy
- Where
- 33 sites in Germany
- Volunteers
- 360 people
- Sponsor
- Hoffmann-La Roche
Diffuse Large B-cell Lymphoma
The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP
The purpose of this study is to determine the effective of Yt90-Zevalin therapy in patients with diffuse large B-cell lymphoma that have achieved at least an unconfirmed partial remission after 6 cycles of CHOP therapy.
- Trial name
- NCT00440583
- Testing
- chemotherapy followed by Zevalin
- Where
- Thailand
- Volunteers
- 15 people
- Sponsor
- Mahidol University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.